Home
    • Plans Blog Contact
    bioAffinity Technologies Inc logo

    bioAffinity Technologies Inc

    BIAF
    Last price US$0.66
    Market cap US$3.4m
    12M price change N/A
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    IQVIA Holdings IncIQV Industry peer Agilent Technologies IncA Industry peer Thermo Fisher Scientific IncTMO Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    bioAffinity Technologies Inc Overview

    Industry: Diagnostics & Research

    Sector: Healthcare

    bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas. bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other d Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for bioAffinity Technologies Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Mar 13, 2026

    Quarterly result summary

    Revenue was $6.2M (-34% YoY). Net loss was -$14.9M (from $9M). R&D expense was $1.4M.

    Revenue $6.2M -34% YoY
    Net loss -$14.9M from $9M
    R&D expense $1.4M reported
    Cash $6.5M reported

    What changed

    • Revenue -34% YoY to $6.2M.
    • Net loss was -$14.9M (from $9M).

    Guidance / outlook

    We expect the trend to accelerate in 2026 as we expand our sales force into new markets.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q May 11, 2026 SEC filing 8-K May 08, 2026 SEC filing 10-K Mar 16, 2026 SEC filing 8-K Mar 13, 2026 SEC filing 8-K Nov 14, 2025 Earnings release Earnings release Nov 14, 2025 SEC filing 10-Q Nov 14, 2025 SEC filing 10-Q Aug 14, 2025 SEC filing 8-K Aug 14, 2025 Earnings release Earnings release Aug 14, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 0.00/5
    bioAffinity Technologies Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Diagnostics & Research industry , IQVIA Holdings Inc , Agilent Technologies Inc , Thermo Fisher Scientific Inc are companies with high ratings.

    Return on Equity

    Score 3.31/5
    bioAffinity Technologies Inc stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    bioAffinity ... BIAF US$3.4m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 4.24/5
    bioAffinity Technologies Inc commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    bioAffinity ... BIAF US$3.4m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Diagnostics & Research industry , IQVIA Holdings Inc , Agilent Technologies Inc , Thermo Fisher Scientific Inc are companies with high ratings.

    Leverage

    Score 4.80/5
    bioAffinity Technologies Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    bioAffinity ... BIAF US$3.4m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    bioAffinity Technologies Inc logo

    bioAffinity Technologies Inc

    US$0.66

    US$3.4m

    -6.22%

    N/A